Keywords: actelion, bids, million, firm, cotherix, gains, rights
Actelion bids $420 million for US firm CoTherix; gains rights to Ventavis
Article | 27 November 2006
In a move that will strengthen its pulmonary arterial hypertension therapy franchise, Swiss biopharmaceutical company Actelion has entered into a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
